Proton pump inhibitors improve survival in systemic sclerosis-associated ILD

The use of proton pump inhibitors improves overall and progression-free survival in patients with systemic sclerosis-associated interstitial lung disease, according to data published in Rheumatology.Meanwhile, the researchers additionally concluded that gastroesophageal reflux disease (GERD) has no impact on survival in either SSc or SSc-ILD.“GERD, which is frequently treated with proton-pump inhibitors (PPI), is common in SSc and pre-clinical data have suggested a persistent inflammation of the lung tissue caused by micro-aspiration of acidic reflux material potentially leading toRead More